Monte Rosa Therapeutics, Inc. (GLUE): Price and Financial Metrics
GLUE Price/Volume Stats
| Current price | $5.85 | 52-week high | $8.84 |
| Prev. close | $5.92 | 52-week low | $2.44 |
| Day low | $5.54 | Volume | 112,700 |
| Day high | $6.03 | Avg. volume | 149,584 |
| 50-day MA | $6.36 | Dividend yield | N/A |
| 200-day MA | $5.52 | Market Cap | 293.38M |
GLUE Stock Price Chart Interactive Chart >
Monte Rosa Therapeutics, Inc. (GLUE) Company Bio
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is based in Boston, Massachusetts.
Latest GLUE News From Around the Web
Below are the latest news stories about MONTE ROSA THERAPEUTICS INC that investors may wish to consider to help them evaluate GLUE as an investment opportunity.
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare ConferenceBOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in a fireside discussion at the 35th Annual Piper Sandler Healthcare Conference in New York City on Tuesday, November 28, 2023, at 3:30 p.m. ET. A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, |
Monte Rosa Therapeutics Inc (GLUE) Reports Q3 2023 Financial Results and Strategic DevelopmentsKey Clinical Advancements and Financial Highlights |
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateInterim data from Phase 1/2 clinical trial of MRT-2359 demonstrated tumor reductions in patients with biomarker-positive cancers; recommended Phase 2 dose expected in Q2 2024 Announced strategic collaboration with Roche to discover novel molecular glue degraders targeting cancer and neurological diseases; $50 million upfront payment Presented preclinical data demonstrating that MRT-6160, a VAV1-targeting MGD, attenuates autoimmune disease progression; IND submission expected 1H 2024 Completed $2 |
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory DiseasesData presented support broad potential therapeutic applications of MRT-6160 in a variety of autoimmune and inflammatory disorders driven by underlying dysregulation of T- and B-cells, including rheumatoid arthritis Investigational New Drug filing for MRT-6160 expected in 1H 2024 Data will be presented during Poster Session A on Sunday, November 12, 2023 from 9:00-11:00 am PT BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology com |
Monte Rosa Therapeutics to Participate in Upcoming Investor ConferencesBOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: TD Cowen 7th Annual Fall Oncology Innovation Summit (virtual) – Fireside Chat, November 3, 2023, 1:00 p.m. ETJefferies London Healthcare Conference (London, UK) – Investor meetings, November 14-15, 2023 The webcasted presentation will be acce |
GLUE Price Returns
| 1-mo | -22.92% |
| 3-mo | 15.84% |
| 6-mo | 120.75% |
| 1-year | 2.27% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 3.54% |
| 2023 | -25.76% |
| 2022 | -62.73% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...